IL270838A - Methods for treating merkel cell carcinoma (mcc) using nk-92 cells - Google Patents

Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Info

Publication number
IL270838A
IL270838A IL270838A IL27083819A IL270838A IL 270838 A IL270838 A IL 270838A IL 270838 A IL270838 A IL 270838A IL 27083819 A IL27083819 A IL 27083819A IL 270838 A IL270838 A IL 270838A
Authority
IL
Israel
Prior art keywords
mcc
cells
methods
cell carcinoma
merkel cell
Prior art date
Application number
IL270838A
Other languages
English (en)
Hebrew (he)
Inventor
Laurent Boissel
Tien Lee
Hans Klingemann
Original Assignee
Nantkwest Inc
Laurent Boissel
Tien Lee
Hans Klingemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantkwest Inc, Laurent Boissel, Tien Lee, Hans Klingemann filed Critical Nantkwest Inc
Publication of IL270838A publication Critical patent/IL270838A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL270838A 2017-06-20 2019-11-21 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells IL270838A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522335P 2017-06-20 2017-06-20
PCT/US2018/038308 WO2018236887A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Publications (1)

Publication Number Publication Date
IL270838A true IL270838A (en) 2020-01-30

Family

ID=62875317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270838A IL270838A (en) 2017-06-20 2019-11-21 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Country Status (9)

Country Link
US (1) US20200171087A1 (enExample)
EP (1) EP3641790A1 (enExample)
JP (1) JP2020524164A (enExample)
KR (1) KR20200017494A (enExample)
CN (1) CN110753551A (enExample)
AU (1) AU2018288712A1 (enExample)
CA (1) CA3066463A1 (enExample)
IL (1) IL270838A (enExample)
WO (1) WO2018236887A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476640B1 (ko) 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use

Also Published As

Publication number Publication date
EP3641790A1 (en) 2020-04-29
KR20200017494A (ko) 2020-02-18
CA3066463A1 (en) 2018-12-27
AU2018288712A1 (en) 2019-12-12
JP2020524164A (ja) 2020-08-13
US20200171087A1 (en) 2020-06-04
WO2018236887A1 (en) 2018-12-27
CN110753551A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
IL283733A (en) Methods of cancer treatment using activated t cells
IL255884A (en) Modified nk-92 cells for cancer treatment
EP3484994A4 (en) A crispr-cas system for an algal host cell
EP3580354A4 (en) HIGH FLOW SINGLE-CELL POLYOMIC
EP3703712A4 (en) PRIMITIVE CELL GENE EDITING
DK3596123T3 (da) FC-optimeret anti-CD25 til tumorspecifik celledepletering
CL2020000951A1 (es) Célula.
DE112019004066A5 (de) Elektrochemisches system
EP4004201A4 (en) Single cell analysis
EP3802802A4 (en) CELLULAR THERAPY
DE112018005667A5 (de) Lösungsmittelfreier festkörperelektrolyt
EP3647407A4 (en) CELL CULTURE DEVICE
EP3780136A4 (en) CELL
IL262989A (en) Methods of treating autoimmune disease using allogeneic t cells
BR112016018562A2 (pt) método de operação de células eletroquímicas compreendendo combustível eletrodepositado.
EP4057310A4 (en) ELECTROLYTIC SOLUTION
EP3358627C0 (en) SOLAR CELL
DK3460052T3 (da) Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer
LT3375889T (lt) Vienos ląstelės analizė
BR112017022815A2 (pt) material de eletrólito estável e material de solvente contendo o mesmo.
EP3518302A4 (en) SOLAR CELL
DK3253906T3 (da) Elektrolyt til elektroplettering
EP3448986A4 (en) CELL CULTURE
EP3642577A4 (en) COMPACT SPECTROMETER MODULES
IL284060A (en) Deionization fuel cell system